BR112016011166A2 - - Google Patents

Info

Publication number
BR112016011166A2
BR112016011166A2 BR112016011166A BR112016011166A BR112016011166A2 BR 112016011166 A2 BR112016011166 A2 BR 112016011166A2 BR 112016011166 A BR112016011166 A BR 112016011166A BR 112016011166 A BR112016011166 A BR 112016011166A BR 112016011166 A2 BR112016011166 A2 BR 112016011166A2
Authority
BR
Brazil
Application number
BR112016011166A
Other languages
Portuguese (pt)
Other versions
BR112016011166A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016011166A2 publication Critical patent/BR112016011166A2/pt
Publication of BR112016011166A8 publication Critical patent/BR112016011166A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
BR112016011166A 2013-11-19 2014-11-19 Formulação farmacêutica, uso de ll-37 ou um sal farmaceuticamente aceitável do mesmo, e, método para tratar topicamente uma úlcera crônica BR112016011166A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2013/053053 WO2015075406A1 (en) 2013-11-19 2013-11-19 New treatment of chronic ulcers
PCT/GB2014/053415 WO2015075441A1 (en) 2013-11-19 2014-11-19 New treatment of chronic ulcers

Publications (2)

Publication Number Publication Date
BR112016011166A2 true BR112016011166A2 (enExample) 2017-08-08
BR112016011166A8 BR112016011166A8 (pt) 2022-06-28

Family

ID=49998562

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011166A BR112016011166A8 (pt) 2013-11-19 2014-11-19 Formulação farmacêutica, uso de ll-37 ou um sal farmaceuticamente aceitável do mesmo, e, método para tratar topicamente uma úlcera crônica

Country Status (15)

Country Link
US (3) US10226508B2 (enExample)
EP (1) EP3071216B1 (enExample)
JP (1) JP6539268B2 (enExample)
KR (1) KR102360938B1 (enExample)
CN (1) CN105939726A (enExample)
AU (1) AU2014351607B2 (enExample)
BR (1) BR112016011166A8 (enExample)
CA (1) CA2927557C (enExample)
ES (1) ES2925876T3 (enExample)
MX (1) MX379357B (enExample)
PL (1) PL3071216T3 (enExample)
RU (1) RU2707254C1 (enExample)
TW (1) TWI698251B (enExample)
WO (2) WO2015075406A1 (enExample)
ZA (1) ZA201604110B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808376D0 (en) 2008-05-08 2008-06-18 Bristol Myers Squibb Co Wound dressing
GB0817796D0 (en) 2008-09-29 2008-11-05 Convatec Inc wound dressing
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
EP4162968A1 (en) 2010-12-08 2023-04-12 ConvaTec Technologies Inc. System for removing exudates from a wound site
CN103347561B (zh) 2010-12-08 2016-09-07 康沃特克科技公司 用于评估伤口分泌液的集成系统
JP6151186B2 (ja) 2010-12-08 2017-06-21 コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ 創傷滲出液システム付属装置
GB201115182D0 (en) 2011-09-02 2011-10-19 Trio Healthcare Ltd Skin contact material
GB2497406A (en) 2011-11-29 2013-06-12 Webtec Converting Llc Dressing with a perforated binder layer
GB201120693D0 (en) 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
CN105008611A (zh) 2012-12-20 2015-10-28 康沃特克科技公司 化学改性的纤维素纤维的处理
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
BR112017023392A2 (pt) 2015-04-28 2018-07-17 Convatec Technologies Inc nanofibras antibacterianas
GB2543544A (en) 2015-10-21 2017-04-26 Brightwake Ltd Wound dressing
CA3019436A1 (en) 2016-03-30 2017-10-05 Qualizyme Diagnostics Gmbh & Co Kg Detecting microbial infection in wounds
CN109310528B (zh) 2016-03-30 2021-07-20 康沃特克科技公司 检测伤口中的微生物感染
GB201608099D0 (en) 2016-05-09 2016-06-22 Convatec Technologies Inc Negative pressure wound dressing
TW201805034A (zh) 2016-07-08 2018-02-16 美商康瓦鐵克科技股份有限公司 彈性的負壓系統
US11266774B2 (en) 2016-07-08 2022-03-08 Convatec Technologies Inc. Fluid collection apparatus
PL3481360T3 (pl) 2016-07-08 2022-05-02 Convatec Technologies Inc. Wykrywanie przepływu płynu
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
EP3638251B1 (en) * 2017-06-12 2024-03-06 Lakewood Amedex, Inc. Bisphosphocin gel formulations and uses thereof
US12161792B2 (en) 2017-11-16 2024-12-10 Convatec Limited Fluid collection apparatus
BR112021006954A2 (pt) 2018-10-17 2021-07-20 Lakewood Amedex, Inc. métodos e composições para tratar mucosite oral
JP7511585B2 (ja) 2019-06-03 2024-07-05 コンバテック リミティド 病原体を破壊して封じ込めるための方法およびデバイス
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
WO1997039764A1 (fr) 1996-04-23 1997-10-30 Toray Industries, Inc. Agent anti-pylori
ATE264119T1 (de) * 1996-07-11 2004-04-15 Coloplast As Hydrokolloid-wundgel
US6861067B2 (en) * 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
US6835713B2 (en) 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7262179B2 (en) * 2003-05-28 2007-08-28 Bristol-Myers Squibb Company Wound care compositions
EP1621205A1 (en) * 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
ZA200600686B (en) * 2006-01-24 2006-04-26 Jacobus F Mouton A wound dressing
WO2008088922A2 (en) * 2007-01-19 2008-07-24 Genentech, Inc. Prevention of hydrogel viscosity loss
AU2008269575A1 (en) * 2007-06-25 2008-12-31 Lipopeptide Ab New medical products
CA2734577A1 (en) * 2007-08-16 2009-02-26 Carnegie Mellon University Inflammation-regulating compositions and methods
DK2222327T3 (en) * 2007-12-28 2017-05-15 Augustinus Bader TOPICAL USE AND FORMULATION OF ERYTHROPOIETIN FOR HEALTH CARE
CN102665765A (zh) * 2009-11-03 2012-09-12 立普妥公司 促进创伤愈合的组合物
JP2013537195A (ja) * 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
US9693936B2 (en) * 2012-03-07 2017-07-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dispersions in oil of Dead Sea nano sized material preparation and uses therof
US9345744B2 (en) * 2012-04-25 2016-05-24 Musc Foundation For Research Development Peptide-based collagen modulators for wound healing and tissue repair
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers

Also Published As

Publication number Publication date
AU2014351607A1 (en) 2016-06-23
EP3071216B1 (en) 2022-08-03
CN105939726A (zh) 2016-09-14
ZA201604110B (en) 2020-11-25
KR20160088914A (ko) 2016-07-26
RU2707254C1 (ru) 2019-11-25
US20200384077A1 (en) 2020-12-10
EP3071216A1 (en) 2016-09-28
TW201521760A (zh) 2015-06-16
US10709760B2 (en) 2020-07-14
ES2925876T3 (es) 2022-10-20
US20190255147A1 (en) 2019-08-22
US10226508B2 (en) 2019-03-12
US20160271217A1 (en) 2016-09-22
CA2927557C (en) 2023-05-02
KR102360938B1 (ko) 2022-02-09
CA2927557A1 (en) 2015-05-28
MX2016006091A (es) 2016-12-09
JP6539268B2 (ja) 2019-07-03
PL3071216T3 (pl) 2022-11-21
TWI698251B (zh) 2020-07-11
AU2014351607B2 (en) 2020-03-05
US11191810B2 (en) 2021-12-07
WO2015075406A1 (en) 2015-05-28
MX379357B (es) 2025-03-11
RU2016124234A (ru) 2017-12-25
WO2015075441A1 (en) 2015-05-28
BR112016011166A8 (pt) 2022-06-28
JP2016537373A (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
BR112015007533A2 (enExample)
BR112014017733A2 (enExample)
BR112014018502A2 (enExample)
BR112014017739A2 (enExample)
BR112014019326A2 (enExample)
BR112014018480A2 (enExample)
BR112014018516A2 (enExample)
BR112014020341A2 (enExample)
BR112014017855A2 (enExample)
BR112014017765A2 (enExample)
BR112014017669A2 (enExample)
BR112016014583A2 (enExample)
BR112016005219A2 (enExample)
BR112014021878A2 (enExample)
BR112016012711A2 (enExample)
BR112014018468A2 (enExample)
BR112014017901A2 (enExample)
BR112014019204A2 (enExample)
BR112014018207A2 (enExample)
BR112015015948A2 (enExample)
BR112016003040A2 (enExample)
BR112016010966A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112014018578A2 (enExample)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: PROMORE PHARMA AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: PERGASUS AB (SE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.